EP3294273A4 - Anti-interleukin-antikörperzubereitungen zur freisetzung in ein lumen des darmtraktes mit einer einnehmbaren wirkstofffreisetzungsvorrichtung - Google Patents

Anti-interleukin-antikörperzubereitungen zur freisetzung in ein lumen des darmtraktes mit einer einnehmbaren wirkstofffreisetzungsvorrichtung Download PDF

Info

Publication number
EP3294273A4
EP3294273A4 EP16793347.2A EP16793347A EP3294273A4 EP 3294273 A4 EP3294273 A4 EP 3294273A4 EP 16793347 A EP16793347 A EP 16793347A EP 3294273 A4 EP3294273 A4 EP 3294273A4
Authority
EP
European Patent Office
Prior art keywords
lumen
intestinal tract
antibody preparations
delivery device
swallowable drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16793347.2A
Other languages
English (en)
French (fr)
Other versions
EP3294273A1 (de
Inventor
Mir Imran
Radhika KORUPOLU
Elaine TO
Mir Hashim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rani Therapeutics LLC
Original Assignee
Incube Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incube Laboratories LLC filed Critical Incube Laboratories LLC
Publication of EP3294273A1 publication Critical patent/EP3294273A1/de
Publication of EP3294273A4 publication Critical patent/EP3294273A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16793347.2A 2015-05-08 2016-05-09 Anti-interleukin-antikörperzubereitungen zur freisetzung in ein lumen des darmtraktes mit einer einnehmbaren wirkstofffreisetzungsvorrichtung Pending EP3294273A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562159134P 2015-05-08 2015-05-08
PCT/US2016/031548 WO2016183040A1 (en) 2015-05-08 2016-05-09 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Publications (2)

Publication Number Publication Date
EP3294273A1 EP3294273A1 (de) 2018-03-21
EP3294273A4 true EP3294273A4 (de) 2018-12-05

Family

ID=57248408

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16793347.2A Pending EP3294273A4 (de) 2015-05-08 2016-05-09 Anti-interleukin-antikörperzubereitungen zur freisetzung in ein lumen des darmtraktes mit einer einnehmbaren wirkstofffreisetzungsvorrichtung

Country Status (6)

Country Link
EP (1) EP3294273A4 (de)
JP (2) JP7185401B2 (de)
CN (1) CN107835682A (de)
AU (2) AU2016261599B2 (de)
CA (1) CA2984422C (de)
WO (1) WO2016183040A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
JP2018526403A (ja) * 2015-09-08 2018-09-13 インキューブ ラブズ， エルエルシー 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤
CA3046093A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
US20200206132A1 (en) * 2018-12-31 2020-07-02 Incube Labs, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031770A2 (en) * 2006-09-12 2008-03-20 Cosmo Technologies Ltd Pharmaceutical compositions for the oral or rectal administration of protein substances
WO2009063222A2 (en) * 2007-11-15 2009-05-22 Ucl Business Plc Solid compositions
US20120027775A1 (en) * 2010-08-02 2012-02-02 Advanced Technologies And Regenerative Medicine, Llc Absorbable peg-based hydrogels
WO2014066468A1 (en) * 2012-10-25 2014-05-01 Medimmune, Llc Stable, low viscosity antibody formulation
WO2015176031A2 (en) * 2014-05-15 2015-11-19 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024767B2 (ja) * 1979-08-24 1985-06-14 塩野義製薬株式会社 腸溶性硬カプセル剤
WO2006052660A2 (en) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Il-7 receptor blockade to suppress immunity
US8721620B2 (en) * 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
CA2785168C (en) 2009-12-24 2018-04-17 Incube Labs, Llc Swallowable drug delivery device and methods of drug delivery
US8980822B2 (en) * 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9149617B2 (en) * 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
CA2840487C (en) 2011-06-29 2022-09-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
JP6029664B2 (ja) 2011-06-29 2016-11-24 ラニ セラピューティクス， エルエルシー 嚥下可能な薬物送達デバイスを用いる腸管の内腔へ送達するための治療剤製剤
US20150064241A1 (en) * 2013-09-05 2015-03-05 Google Inc. Delivery of Functionalized Particles
AU2016257813B2 (en) * 2015-05-01 2021-05-13 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031770A2 (en) * 2006-09-12 2008-03-20 Cosmo Technologies Ltd Pharmaceutical compositions for the oral or rectal administration of protein substances
WO2009063222A2 (en) * 2007-11-15 2009-05-22 Ucl Business Plc Solid compositions
US20120027775A1 (en) * 2010-08-02 2012-02-02 Advanced Technologies And Regenerative Medicine, Llc Absorbable peg-based hydrogels
WO2014066468A1 (en) * 2012-10-25 2014-05-01 Medimmune, Llc Stable, low viscosity antibody formulation
WO2015176031A2 (en) * 2014-05-15 2015-11-19 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LONNBERG ET AL: "Targeting of interleukin-17 in the treatment of psoriasis", CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 1 September 2014 (2014-09-01), pages 251, XP055328086, DOI: 10.2147/CCID.S67534 *

Also Published As

Publication number Publication date
CA2984422A1 (en) 2016-11-17
CA2984422C (en) 2023-10-17
JP2018520995A (ja) 2018-08-02
JP2021042239A (ja) 2021-03-18
AU2016261599B2 (en) 2021-08-26
AU2016261599A1 (en) 2017-11-23
CN107835682A (zh) 2018-03-23
WO2016183040A1 (en) 2016-11-17
JP7185401B2 (ja) 2022-12-07
AU2021269453A1 (en) 2021-12-16
JP7232805B2 (ja) 2023-03-03
EP3294273A1 (de) 2018-03-21

Similar Documents

Publication Publication Date Title
EP3706720A4 (de) Gerinnungsfaktorpräparate zur verabreichung in gewebe des darmtraktes unter verwendung einer schluckbaren arzneimittelabgabevorrichtung
EP3316872A4 (de) Zubereitung von therapeutischen wirkstoffen zur freisetzung in ein lumen des darmtraktes mit einer einnehmbaren wirkstofffreisetzungsvorrichtung
EP3347050A4 (de) Pcsk9-antikörper-präparate zur freisetzung in ein lumen des darmtraktes unter verwendung einer einnehmbaren wirkstofffreisetzungsvorrichtung
PL2726091T3 (pl) Preparaty lecznicze dostarczane do kanału przewodu jelitowego za pomocą połykalnego urządzenia dostarczającego lek
EP3615113A4 (de) Antriebsmechanismus für medizinischen inhalator
EP3970767A4 (de) Arzneimittelinfusionsvorrichtung
EP3302265A4 (de) Wirkstofffreisetzungskapsel
EP3437676A4 (de) Vorrichtung zur verabreichung eines flüssigen medikaments
EP4003458A4 (de) Unilateral angetriebene arzneimittelinfusionsvorrichtung
EP3962516A4 (de) Gerinnungsfaktorpräparate zur verabreichung in gewebe des darmtraktes unter verwendung einer schluckbaren arzneimittelabgabevorrichtung
EP3294273A4 (de) Anti-interleukin-antikörperzubereitungen zur freisetzung in ein lumen des darmtraktes mit einer einnehmbaren wirkstofffreisetzungsvorrichtung
EP3445416A4 (de) Enterales wirkstofffreisetzungssystem
EP3905999A4 (de) Therapeutikumpräparate zur freisetzung in ein lumen des darmtraktes mittels einnehmbarer wirkstofffreisetzungsvorrichtung
EP3260148A4 (de) Verabreichungsvorrichtung für flüssigarzneimittel
EP3263155A4 (de) Vorrichtung zur verabreichung von arzneimittellösungen
EP3597235A4 (de) Vorrichtung zur verabreichung einer medizinischen flüssigkeit
EP3900727A4 (de) Immunitätsmechanismus und therapeutisches arzneimittel für gastrointestinale erkrankungen
IL279127A (en) Dispensing devices for drug administration
EP3925643A4 (de) Vorrichtung zur verabreichung von flüssigen medikamenten
EP3801703A4 (de) System zur verabreichung von körperintegrierten arzneimitteln
EP3925645A4 (de) Vorrichtung zur verabreichung von flüssigen medikamenten
EP3846885B8 (de) Medikamentenverabreichungsvorrichtung
EP3351286A4 (de) Vorrichtung zur verabreichung einer arzneimittellösung
EP3661576A4 (de) Medizinischer vernebler zur schnellen arzneimittelabgabe
EP3590513A4 (de) Arzneimittel

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171027

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181029

RIC1 Information provided on ipc code assigned before grant

Ipc: A61F 13/00 20060101ALI20181023BHEP

Ipc: A61K 9/20 20060101AFI20181023BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RANI THERAPEUTICS, LLC

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524